Xiaolin Yin

Abstract Allogeneic stem cell transplantation (allo-HSCT) has recently been approved as standard therapy for transfusion-dependent thalassemia (TDT) but remains limited to the use of HLA-matched sibling donors (MSDs), due to a lack of large-scale prospective studies evaluating the use of grafts from alternative donors. Here, we report the results of a non-randomised, interventional, phase 4 clinical trial evaluating allo-HSCT from alternative donors for the treatment of TDT.

Keywords oral microbiome oral health esophageal squamous cell carcinoma mediation classification Introduction Oral health problems affect nearly 3.5 billion people globally and remain a substantial public health challenge, especially in underdeveloped regions.1 Increasing evidence links poor oral health to a higher risk of esophageal cancer (EC),2,3,4 which comprises two major pathological subtypes—esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC)—together...

Main text (Developmental Cell 56, 478–493.e1–e11; February 22, 2021) In the originally published version of this paper, due to the similar electrophoretic patterns between the TAL1 and HBBP1 PCR products, the gel image of TAL1 PCR product in Figure 5A was erroneously replaced with that of HBBP1 PCR product from Figure 4F, resulting in duplicated images in Figures 5A and 4F. The authors sincerely apologize for the error, and the corrected version of the image can be found below.